Tirzepatide Reduces Kidney Damage Markers Without Harming Kidney Function — a 14,471-Patient Meta-Analysis
A meta-analysis of 15 RCTs (14,471 patients) found tirzepatide significantly reduced urinary albumin — an early marker of kidney damage — without negatively affecting kidney filtration rate, and had no increased risk of adverse kidney events.
Quick Facts
What This Study Found
Tirzepatide 10 mg reduced UACR by 26.95% more than placebo (p<0.05) and 15 mg reduced it by a similar significant margin (p=0.0008) over 26-72 weeks. All tirzepatide doses outperformed insulin for UACR reduction. The benefit was greater in type 2 diabetes patients (MD -33.25%) than in obese patients without diabetes (MD -7.93%, p=0.001 for difference).
eGFR was comparable across all tirzepatide doses versus insulin (no statistically significant differences). Tirzepatide showed no increased risk of adverse renal events, UTI, nephrolithiasis, acute kidney injury, or renal cancer compared to placebo, insulin, or GLP-1 receptor agonists.
Key Numbers
How They Did This
Systematic review and meta-analysis of 15 randomized controlled trials (n=14,471) identified from multiple electronic databases. Trials compared tirzepatide to placebo, insulin, or GLP-1 RAs in patients with type 2 diabetes or obesity. Primary outcomes: percent change from baseline in UACR and absolute change in eGFR. Secondary outcome: renal safety events. Random-effects models were used. Most included studies had low risk of bias.
Why This Research Matters
Kidney disease is one of the most devastating complications of diabetes, eventually requiring dialysis or transplant. GLP-1 agonists like semaglutide have shown some kidney benefits, and this meta-analysis provides the first comprehensive evidence that tirzepatide (which targets both GLP-1 and GIP receptors) also protects the kidneys. Since tirzepatide is rapidly becoming one of the most prescribed drugs worldwide, confirming its kidney safety and potential benefits is critical for the millions of patients taking it.
The Bigger Picture
The SURPASS and SURMOUNT trial programs established tirzepatide's efficacy for blood sugar and weight, but kidney outcomes weren't primary endpoints. This meta-analysis fills that gap, showing early kidney-protective signals similar to what's been seen with GLP-1 RAs. Eli Lilly is conducting a dedicated kidney outcomes trial (TRANSCEND) that will provide definitive answers. If confirmed, kidney protection would add another major indication to tirzepatide's already impressive profile — alongside diabetes, obesity, sleep apnea, and potentially heart failure.
What This Study Doesn't Tell Us
Follow-up was only 26-72 weeks — too short to see hard kidney endpoints like eGFR decline, dialysis, or renal death. UACR reduction is a surrogate marker; whether it translates to actual kidney disease prevention requires longer trials. The greater UACR benefit in diabetes vs. obesity-only patients may reflect higher baseline albuminuria rather than differential drug effect. The dedicated kidney outcomes trial (TRANSCEND) is needed for definitive evidence.
Questions This Raises
- ?Will the TRANSCEND kidney outcomes trial confirm that tirzepatide's UACR reduction translates to actual prevention of kidney disease progression?
- ?Is tirzepatide's kidney benefit driven by the GLP-1 component, the GIP component, or a synergistic effect of both?
- ?Should kidney protection become a factor in choosing between tirzepatide and semaglutide for patients with early diabetic kidney disease?
Trust & Context
- Key Stat:
- -33.25% UACR reduction in T2D Tirzepatide reduced urinary albumin — an early marker of kidney damage — by a third in type 2 diabetes patients compared to placebo
- Evidence Grade:
- This is a meta-analysis of 15 randomized controlled trials with mostly low risk of bias and a large total sample (14,471). This represents strong evidence for kidney safety and promising evidence for kidney benefit, though the surrogate endpoint (UACR) requires confirmation with hard kidney outcomes in dedicated trials.
- Study Age:
- Published in 2025, this is a very current meta-analysis capturing all available RCT data on tirzepatide's kidney effects. A dedicated kidney outcomes trial (TRANSCEND) is underway and will provide more definitive evidence.
- Original Title:
- Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis.
- Published In:
- World journal of diabetes, 16(2), 101282 (2025)
- Authors:
- Kamrul-Hasan, Abm(3), Patra, Shinjan, Dutta, Deep(10), Nagendra, Lakshmi, Muntahi-Reza, Afm, Borozan, Sanja, Pappachan, Joseph M
- Database ID:
- RPEP-11695
Evidence Hierarchy
Frequently Asked Questions
Does tirzepatide protect the kidneys?
This meta-analysis suggests it may. Tirzepatide significantly reduced urinary albumin — an early sign of kidney damage — without harming kidney filtration rate. The effect was strongest in people with type 2 diabetes. However, these are surrogate markers measured over months; whether tirzepatide actually prevents long-term kidney disease progression requires dedicated trials that are currently underway.
Is tirzepatide safe for people with kidney problems?
Based on this analysis, yes — tirzepatide showed no increased risk of acute kidney injury, kidney infections, kidney stones, or kidney cancer compared to placebo, insulin, or GLP-1 drugs. In fact, the kidney markers generally improved. However, patients with advanced kidney disease should consult their doctor, as most trial participants had relatively preserved kidney function.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11695APA
Kamrul-Hasan, Abm; Patra, Shinjan; Dutta, Deep; Nagendra, Lakshmi; Muntahi-Reza, Afm; Borozan, Sanja; Pappachan, Joseph M. (2025). Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis.. World journal of diabetes, 16(2), 101282. https://doi.org/10.4239/wjd.v16.i2.101282
MLA
Kamrul-Hasan, Abm, et al. "Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis.." World journal of diabetes, 2025. https://doi.org/10.4239/wjd.v16.i2.101282
RethinkPeptides
RethinkPeptides Research Database. "Renal effects and safety of tirzepatide in subjects with and..." RPEP-11695. Retrieved from https://rethinkpeptides.com/research/kamrul-hasan-2025-renal-effects-and-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.